Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03595579 · ClinicalTrials.gov registry record · Phase 2

Assessing Symptomatic Clinical Episodes in Depression

A Phase 2 study, sponsored by Axsome Therapeutics.

Completed
Registry status
Phase 2
Development phase
97
Enrollment target

NCT03595579 is a Phase 2 study that has completed, run by Axsome Therapeutics. The registered enrollment target is 97 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03595579, a Phase 2 study, has completed, sponsored by Axsome Therapeutics.

COMPLETED
Registry status
Phase 2
Development phase
97 participants
Enrollment target

Study Summary

Randomized, Double-Blind, Active-Controlled Study of AXS-05 for MDD.

Interventions

  • DRUG AXS-05
  • DRUG Bupropion

Trial Details

FieldValue
Enrollment Target 97 participants
Start Date 2018-05-30
Est. Completion 2019-01-07
Phase Phase 2

Sponsor

Axsome Therapeutics

28 total trials

What the Registry Record Tells You About NCT03595579

The ClinicalTrials.gov registry entry for NCT03595579 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 97 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Axsome Therapeutics, which has 28 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which AXS-05 is the first listed.

NCT03595579 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03595579 about?

NCT03595579 is a clinical study titled "Assessing Symptomatic Clinical Episodes in Depression". Randomized, Double-Blind, Active-Controlled Study of AXS-05 for MDD.

What is the current status of trial NCT03595579?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 97 participants. The study started on 2018-05-30. Estimated completion is 2019-01-07.

What interventions are being tested in trial NCT03595579?

The interventions under investigation include: AXS-05 (DRUG), Bupropion (DRUG).

Who is sponsoring clinical trial NCT03595579?

This trial is sponsored by Axsome Therapeutics, which has 28 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.